Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis

被引：39
|
作者：
Selvaggio, Anna S. [1 ]
Noble, Paul W. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA
来源：
ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷
关键词：
pirfenidone; idiopathic pulmonary fibrosis; interstitial lung disease; Esbriet (R); NECROSIS-FACTOR-ALPHA; OPEN-LABEL; PHASE-3; TRIAL; DOUBLE-BLIND; SURVIVAL; ACETYLCYSTEINE; PROLIFERATION; ACTIVATION; CAPACITY; RECEPTOR;
D O I：
10.1146/annurev-med-120214-013614
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease that has long eluded therapy. Prognosis remains very poor, and currently lung transplantation offers the only hope of survival. Recently, great strides have been made in the development of pharmaceutical therapy to treat IPF. Pirfenidone, an oral antifibrotic agent, has been shown to slow progression of the disease and improve progression-free survival, offering new hope for patients suffering from IPF.
引用
收藏
页码：487 / 495
页数：9
相关论文
共 50 条
  • [21] Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
    Finnerty, James Patrick
    Ponnuswamy, Aravind
    Dutta, Prosjenjit
    Abdelaziz, Ammar
    Kamil, Hafiz
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [22] Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis
    Marcos Ribes, Borja
    Sancho-Chust, Jose N.
    Talens, Amparo
    Arlandis, Mar
    Herraiz, Paola
    Chiner, Eusebi
    Aznar, Teresa
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (06) : 350 - 354
  • [23] Optimising pirfenidone dosage regimens in idiopathic pulmonary fibrosis: towards a guide for personalised treatment
    Tsyplakova, Nastia
    Ismailos, Georgios
    Karalis, Vangelis D.
    XENOBIOTICA, 2025, 55 (01) : 25 - 36
  • [24] Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program
    Richeldi, Luca
    du Bois, Roland M.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (04) : 473 - 481
  • [25] Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
    Salih, Goran Nadir
    Shaker, Saher Burhan
    Madsen, Helle Dall
    Bendstrup, Elisabeth
    EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2016, 3
  • [26] Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosis
    Behr, Juergen
    Bonella, Francesco
    Frye, Bjoern C.
    Guenther, Andreas
    Hagmeyer, Lars
    Henes, Joerg
    Klemm, Philipp
    Koschel, Dirk
    Kreuter, Michael
    Leuschner, Gabriela
    Nowak, Dennis
    Prasse, Antje
    Quadder, Bernd
    Sitter, Helmut
    Costabel, Ulrich
    PNEUMOLOGIE, 2023, 77 (02): : 94 - 119
  • [27] A new era of drug therapy for idiopathic pulmonary fibrosis
    Crooks, Michael G.
    Hart, Simon P.
    LANCET RESPIRATORY MEDICINE, 2014, 2 (12) : 964 - 966
  • [28] Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
    Ravaglia, Claudia
    Gurioli, Carlo
    Romagnoli, Micaela
    Casoni, GianLuca
    Tomassetti, Sara
    Gurioli, Christian
    Poletti, Venerino
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [29] Comparative study between pirfenidone and traditional drugs in treatment of idiopathic pulmonary fibrosis
    Nafee, Ramadan M.
    Shoman, Waheed M.
    AboZaid, Mohammed M. N.
    El Wahed, Dalia A.
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2019, 68 (02): : 245 - 251
  • [30] PREDICTIVE FACTORS FOR THE EFFECT OF PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS
    Ichimura, Yasunori
    Tsushima, Kenji
    Matsumura, Takuma
    Yamagishi, Kazutaka
    Abe, Mitsuhiro
    Ikari, Jun
    Terada, Jiro
    Tastumi, Koichiro
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2017, 34 (04) : 290 - 299
12345